The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

The present invention provides a method for the treatment of retinoblastoma comprising administering a composition comprising a therapeutically active agent to a subject in need thereof by injection of the composition into the vitreous cavity, suprachoroidal space, supraciliary space or sub-Tenon's space of the eye adjacent to a retinoblastoma tumour. The invention also provides a composition comprising at least one therapeutically active agent selected from the group consisting of a Bcl-2 inhibitor or a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the composition is for administration into the vitreous cavity, suprachoroidal space, sub-Tenon's space, or supraciliary space adjacent to a retinoblastoma tumour in an eye. Also provided is a kit comprising a Bcl-2 inhibitor and a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the Bcl-2 inhibitor and the topoisomerase inhibitor are for separate, simultaneous or sequential administration. The invention also provides a kit comprising a composition comprising at least one therapeutically active agent and a cannulation or catheterization device for use in the treatment of retinoblastoma.

The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): Formula (A).

##STR00001##

The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): Formula (A).

##STR00001##

In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Among the various aspects of the present disclosure is the provision of OXTR chaperones and methods of use thereof. An aspect of the present disclosure provides for a method of increasing the display of oxytocin receptor (OXTR) on a plasma membrane in a cell of a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Another aspect of the present disclosure provides for a method of increasing or restoring oxytocin sensitivity in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Yet another aspect of the present disclosure provides for a method of increasing the efficacy of oxytocin or synthetic oxytocin in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface.